Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/19/2026 | $6.00 | Outperform | Wolfe Research |
| 3/16/2026 | $12.00 | Neutral → Overweight | Analyst |
| 1/20/2026 | $10.00 | Buy | Guggenheim |
| 9/22/2025 | $6.00 | Overweight | Cantor Fitzgerald |
| 9/17/2025 | $3.50 | Overweight | Barclays |
| 7/31/2025 | $7.00 | Outperform | Oppenheimer |
| 5/15/2025 | $5.00 | Neutral → Buy | H.C. Wainwright |
| 4/14/2025 | $3.25 → $2.50 | Overweight | Piper Sandler |
Wolfe Research initiated coverage of CytomX Therapeutics with a rating of Outperform and set a new price target of $6.00
Analyst upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $12.00
Guggenheim initiated coverage of CytomX Therapeutics with a rating of Buy and set a new price target of $10.00
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Thursday, May 7, 2026, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to jo
- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for mid-year with goal to align on potential Varseta-M registrational trial design in late line CRC - - Varseta-M Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Initial CX-801 PROBODY Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to host conference call today at 8 a.m. ET / 5 a.m. PT - SOUTH SAN FRANCISCO, Calif., M
- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Grade 3 diarrhea rate of 10% in ongoing dose optimization cohorts - - FDA interactions targeted for mid-year with goal to align on potential registrational trial design in late-line colorectal cancer (CRC) - - Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Conference call on Monday, March 16 at 8:00 a.m. ET - SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs. In this role, Dr. Gokhale will lead CytomX's global regulatory strategy and oversee regulatory engagement to support the continued advancement of the Company's PROBODY® pipeline through clinical development and toward potential commercialization. "Mamata brings deep global regulatory expertise and a proven track record of advancing oncology assets through late-stage development, global approvals and commercializ
SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Rachael Lester as Senior Vice President, Chief Business Officer. In this role, Ms. Lester will lead the Company's strategy and business development functions. "Rachael brings a wealth of experience in strategic planning and business development across the biopharmaceutical industry and joins CytomX at a time when our platform and pipeline are well positioned to deliver meaningful advances in the treatment of many cancers," said Sean McCarthy, D.Phil., president, chief executive offic
SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)
SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY® and Regeneron's Veloci-Bi® platforms - - CytomX to receive $37 million target selection payment for two additional programs selected - - Regeneron secures option to select up to 6 additional future targets bringing total potential target nomination, research, development, regulatory and sales-based milestones covered under the collaboration to up to approximately ~$4 billion - SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX) today announced an expansion of its collaboration and licensing agree
SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in June. Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026 Fireside Chat: 3:10 p.m. ETLocation: New York, NY Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Wednesday, June 10, 2026Fireside Chat: 9:20 a.m. ETLocation: Miami, FL A live webcast of the presentation will be available on the Events and Presentations page of CytomX's website at www.cytomx.com. In addition, management will be available for one-o
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs. In this role, Dr. Gokhale will lead CytomX's global regulatory strategy and oversee regulatory engagement to support the continued advancement of the Company's PROBODY® pipeline through clinical development and toward potential commercialization. "Mamata brings deep global regulatory expertise and a proven track record of advancing oncology assets through late-stage development, global approvals and commercializ